NZ630465A - Combination therapy involving a vascular disrupting agent and an agent which targets hypoxia - Google Patents
Combination therapy involving a vascular disrupting agent and an agent which targets hypoxiaInfo
- Publication number
- NZ630465A NZ630465A NZ630465A NZ63046513A NZ630465A NZ 630465 A NZ630465 A NZ 630465A NZ 630465 A NZ630465 A NZ 630465A NZ 63046513 A NZ63046513 A NZ 63046513A NZ 630465 A NZ630465 A NZ 630465A
- Authority
- NZ
- New Zealand
- Prior art keywords
- agent
- combination therapy
- vascular disrupting
- therapy involving
- targets hypoxia
- Prior art date
Links
- 239000004066 vascular targeting agent Substances 0.000 title abstract 4
- 206010021143 Hypoxia Diseases 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 title abstract 3
- 230000007954 hypoxia Effects 0.000 title abstract 3
- 238000002648 combination therapy Methods 0.000 title 1
- 230000008685 targeting Effects 0.000 abstract 2
- 239000003798 L01XE11 - Pazopanib Substances 0.000 abstract 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 abstract 1
- 229960001467 bortezomib Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical group C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 abstract 1
- 229960000639 pazopanib Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2012902291A AU2012902291A0 (en) | 2012-06-01 | Combination Therapy | |
| PCT/AU2013/000581 WO2013177633A1 (en) | 2012-06-01 | 2013-06-03 | Combination therapy involving a vascular disrupting agent and an agent which targets hypoxia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ630465A true NZ630465A (en) | 2015-09-25 |
Family
ID=49672192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ630465A NZ630465A (en) | 2012-06-01 | 2013-06-03 | Combination therapy involving a vascular disrupting agent and an agent which targets hypoxia |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20150133401A1 (enExample) |
| EP (1) | EP2854796B1 (enExample) |
| JP (1) | JP6005855B2 (enExample) |
| CN (1) | CN104703595B (enExample) |
| AU (2) | AU2013204313C1 (enExample) |
| CA (1) | CA2874778A1 (enExample) |
| IL (1) | IL235927A (enExample) |
| NZ (1) | NZ630465A (enExample) |
| WO (1) | WO2013177633A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2978640C (en) * | 2015-03-05 | 2023-05-23 | Bionomics Limited | Combination treatment protocol |
| WO2016144636A1 (en) * | 2015-03-06 | 2016-09-15 | Beyondspring Pharmaceuticals, Inc. | Method of treating a brain tumor |
| HK1249052A1 (zh) | 2015-03-06 | 2018-10-26 | BeyondSpring Pharmaceuticals Inc. | 治疗与ras突变相关的癌症的方法 |
| EP3334726B1 (en) | 2015-07-13 | 2022-03-16 | Beyondspring Pharmaceuticals, Inc. | Plinabulin compositions |
| US10912748B2 (en) | 2016-02-08 | 2021-02-09 | Beyondspring Pharmaceuticals, Inc. | Compositions containing tucaresol or its analogs |
| CN109475524A (zh) | 2016-06-06 | 2019-03-15 | 万春药业公司 | 用于减少中性粒细胞减少症的组合物和方法 |
| WO2018129381A1 (en) | 2017-01-06 | 2018-07-12 | Beyondspring Pharmaceuticals, Inc. | Tubulin binding compounds and therapeutic use thereof |
| KR20190109479A (ko) | 2017-02-01 | 2019-09-25 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 호중구감소증의 감소 방법 |
| EP4176876A1 (en) * | 2017-09-14 | 2023-05-10 | Lankenau Institute for Medical Research | Methods and compositions for the treatment of cancer |
| WO2019147615A1 (en) | 2018-01-24 | 2019-08-01 | Beyondspring Pharmaceuticals, Inc. | Composition and method for reducing thrombocytopenia via the administration of plinabulin |
| CN110680824A (zh) * | 2018-07-05 | 2020-01-14 | 深圳艾欣达伟医药科技有限公司 | 埃夫索胺的抗癌医药用途 |
| CN109675039A (zh) * | 2018-12-21 | 2019-04-26 | 中国科学院长春应用化学研究所 | 药物组合、抗肿瘤的药物和应用 |
| CN112755188B (zh) * | 2019-11-01 | 2022-03-08 | 中国科学院微生物研究所 | Shmt2抑制剂在制备抑制膀胱癌细胞生长和转移的药物中的应用 |
| EP4319751A4 (en) | 2021-04-09 | 2025-02-26 | Beyondspring Pharmaceuticals, Inc. | THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATING OF TUMORS |
| JP7762796B2 (ja) | 2021-08-27 | 2025-10-30 | アセンタウィッツ ファーマシューティカルズ リミテッド | Ｐａｒｐ阻害剤に耐性のある患者のｔｈ－３０２による治療 |
| WO2023025291A1 (zh) | 2021-08-27 | 2023-03-02 | 深圳艾欣达伟医药科技有限公司 | 冻干制剂溶液及冻干制剂、方法和用途 |
| US20250186468A1 (en) | 2022-03-15 | 2025-06-12 | Ascentawits Pharmaceuticals, Ltd. | Method for treating patient with brca-mutated cancer |
| EP4509127A4 (en) | 2022-04-15 | 2026-07-15 | Ascentawits Pharmaceuticals Ltd | CANCER TREATMENT METHOD USING TH-302 ALONE OR IN COMBINATION WITH A PARP INHIBITOR |
| EP4529926A4 (en) | 2022-05-23 | 2026-07-01 | Ascentawits Pharmaceuticals Ltd | CANCER TREATMENT METHOD BY COMBINATION OF AN ALKYLATING AGENT PRODRUGATION AND A CELL CYCLE INHIBITOR |
| CN119894521A (zh) | 2022-09-22 | 2025-04-25 | 深圳艾欣达伟医药科技有限公司 | 乏氧激活的化合物在制备治疗癌症患者的药物中的用途 |
| EP4674418A1 (en) | 2023-02-27 | 2026-01-07 | Ascentawits Pharmaceuticals, Ltd. | Solution, freeze-dried formulation, freeze-dried formulation unit package, injection, and injection preparation method |
| EP4755396A1 (en) | 2023-07-28 | 2026-06-10 | Ascentawits Pharmaceuticals, Ltd. | Treatment of p53 gene mutation or defect negative cancer and tumor patients |
| CN121985960A (zh) | 2023-10-18 | 2026-05-05 | 深圳艾欣达伟医药科技有限公司 | 治疗p53基因突变阴性、kras基因突变阳性、brca突变阳性患者 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5340062A (en) | 1992-08-13 | 1994-08-23 | Harmon Industries, Inc. | Train control system integrating dynamic and fixed data |
| US5886025A (en) | 1997-03-06 | 1999-03-23 | Baylor University | Anti-mitotic agents which inhibit tubulin polymerization |
| US6162930A (en) | 1998-03-06 | 2000-12-19 | Baylor University | Anti-mitotic agents which inhibit tubulin polymerization |
| US6849656B1 (en) | 1999-09-17 | 2005-02-01 | Baylor University | Indole-containing and combretastatin-related anti-mitotic and anti-tubulin polymerization agents |
| AUPR283801A0 (en) | 2001-02-01 | 2001-03-01 | Australian National University, The | Chemical compounds and methods |
| US7071190B2 (en) | 2002-02-15 | 2006-07-04 | Rigel Pharmaceuticals, Inc. | Inhibitors to tubulin polymerization |
| US7456214B2 (en) | 2004-05-03 | 2008-11-25 | Baylor University | Chromene-containing compounds with anti-tubulin and vascular targeting activity |
| CA2597447C (en) | 2005-02-14 | 2014-03-25 | Bionomics Limited | Novel tubulin polymerisation inhibitors |
| CA2611712C (en) | 2005-06-14 | 2014-05-13 | Baylor University | Combretastatin analogs with tubulin binding activity |
| CA2640678C (en) * | 2006-02-03 | 2015-03-31 | Bionomics Limited | Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors |
| AU2007332143B2 (en) | 2006-12-11 | 2012-11-08 | Bionomics Limited | Chemical compounds and processes |
| CN102026634B (zh) * | 2008-04-10 | 2014-01-22 | 弗吉尼亚州立邦联大学 | 诱导肿瘤缺氧以治疗癌症 |
| WO2011063469A1 (en) * | 2009-11-27 | 2011-06-03 | Bionomics Limited | Tubulin biomarker assay |
| US20110130367A1 (en) * | 2009-11-27 | 2011-06-02 | Bionomics Limited | Combination Therapy for Treating Proliferative Diseases |
| CA2686587C (en) * | 2009-11-27 | 2018-01-16 | Bionomics Limited | Combination therapy for treating proliferative diseases |
| RU2597844C2 (ru) * | 2010-07-12 | 2016-09-20 | Тресхолд Фармасьютикалз, Инк. | Введение гипоксически активируемых пролекарств и средств, препятствующих ангиогенезу, для лечения рака |
-
2013
- 2013-04-12 AU AU2013204313A patent/AU2013204313C1/en not_active Ceased
- 2013-06-03 JP JP2015514291A patent/JP6005855B2/ja not_active Expired - Fee Related
- 2013-06-03 CN CN201380035499.3A patent/CN104703595B/zh not_active Expired - Fee Related
- 2013-06-03 CA CA2874778A patent/CA2874778A1/en not_active Abandoned
- 2013-06-03 US US14/404,782 patent/US20150133401A1/en not_active Abandoned
- 2013-06-03 AU AU2013270425A patent/AU2013270425A1/en not_active Abandoned
- 2013-06-03 EP EP13797528.0A patent/EP2854796B1/en not_active Not-in-force
- 2013-06-03 WO PCT/AU2013/000581 patent/WO2013177633A1/en not_active Ceased
- 2013-06-03 NZ NZ630465A patent/NZ630465A/en not_active IP Right Cessation
-
2014
- 2014-11-26 IL IL235927A patent/IL235927A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| IL235927A0 (en) | 2015-01-29 |
| EP2854796A1 (en) | 2015-04-08 |
| WO2013177633A1 (en) | 2013-12-05 |
| CA2874778A1 (en) | 2013-12-05 |
| EP2854796B1 (en) | 2018-11-14 |
| CN104703595B (zh) | 2017-07-28 |
| EP2854796A4 (en) | 2015-10-14 |
| JP6005855B2 (ja) | 2016-10-12 |
| US20150133401A1 (en) | 2015-05-14 |
| AU2013204313C1 (en) | 2016-04-07 |
| AU2013270425A1 (en) | 2014-12-18 |
| AU2013204313A1 (en) | 2013-12-19 |
| AU2013204313B2 (en) | 2015-09-03 |
| HK1207286A1 (en) | 2016-01-29 |
| CN104703595A (zh) | 2015-06-10 |
| IL235927A (en) | 2017-11-30 |
| JP2015518008A (ja) | 2015-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA515360469B1 (ar) | مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها | |
| MX351892B (es) | Combinaciones de compuestos inhibidores de akt y abiraterona y metodos de uso. | |
| NZ704266A (en) | Inhibitors of alpha-crystallin aggregation for the treatment for cataract | |
| MX345928B (es) | Composiciones terapeuticamente activas y metodos de uso de las mismas. | |
| CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
| NZ629456A (en) | Methods for treating cancer using tor kinase inhibitor combination therapy | |
| PH12015500719A1 (en) | Gdf-8-inhibitors | |
| PH12014500386A1 (en) | Combination treatment for hepatitis c | |
| MX2013012588A (es) | Inhibidores de cinasa. | |
| MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
| PH12016502355A1 (en) | Pharmaceutical composition | |
| GEP201706624B (en) | Triazolopyrazine as brd4 inhibitors and usage thereof for cancer treatment | |
| WO2012142520A3 (en) | Unit dose form for oral administration | |
| MX2014010590A (es) | Terapia de combinacion para trastornos proliferativos. | |
| MX2015017201A (es) | Derivados de pirazolopiridina para uso en el tratamiento del cancer de vejiga. | |
| NZ732511A (en) | Small molecule inhibitors of egfr and pi3k | |
| PH12015502616A1 (en) | Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer | |
| MX2015004362A (es) | Derivados de ketamina. | |
| MX353500B (es) | Compuesto heterociclico. | |
| MX2015016425A (es) | Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades. | |
| NZ631082A (en) | Methods for treating cancer using tor kinase inhibitor combination therapy | |
| TW201613578A (en) | Pharmaceutical combinations | |
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| MX2012013879A (es) | Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas. | |
| ZA201607489B (en) | Combination comprising a glucocorticoid and edo-s101 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 JUN 2018 BY CPA GLOBAL Effective date: 20170505 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 JUN 2019 BY CPA GLOBAL Effective date: 20180503 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 JUN 2020 BY CPA GLOBAL Effective date: 20190502 |
|
| LAPS | Patent lapsed |